CHEMBL3883293 Target Snapshot

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-14

MAP kinase-interacting serine/threonine-protein kinase 1/2 shows clinical signal disease relevance led by cancer. 5 more disease programs remain visible in the same review block. 1 linked drug keeps the current disease frame grounded. Protein identity stays anchored to UniProt Q9HBH9. Start with cancer, then reuse UniProt Q9HBH9 as the stable protein anchor across project notes and exports.

Review focus

Review-ready target frame

Start with cancer, then reuse UniProt Q9HBH9 as the stable protein anchor across project notes and exports.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-14 1 linked drug

Open source guide

Disease program

cancer

MAP kinase-interacting serine/threonine-protein kinase 1/2 shows clinical signal disease relevance led by cancer. 5 more disease programs remain visible in the same review block. 1 linked drug remains visible in the same block.

Start review with cancer because it currently carries clinical signal support. Linked drugs include TOMIVOSERTIB. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Disease source · ChEMBL drug mechanism + indication proxy

Clinical signal Open Targets-ready proxy 1 linked drug

Open disease block

Protein anchor

MAP kinase-interacting serine/threonine-protein kinase 2

Review this target as MAP kinase-interacting serine/threonine-protein kinase 1/2, mapped to UniProt Q9HBH9. ChEMBL maps the protein component as MAP kinase-interacting serine/threonine-protein kinase 2. Sequence length is 465 aa.

Protein source · UniProt accession via ChEMBL component mapping

UniProt Q9HBH9 Protein 465 aa

Open protein block

Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats MAP kinase-interacting serine/threonine-protein kinase 1/2 as ChEMBL target CHEMBL3883293, mapped to UniProt Q9HBH9. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor

MAP kinase-interacting serine/threonine-protein kinase 1/2

PROTEIN FAMILY · Homo sapiens

As of 2026-09-14

ChEMBL target ID

CHEMBL3883293

Primary anchor for compounds, assays, approvals, and exports

ChEMBL 36 via Core Engine As of 2026-09-14

www.ebi.ac.uk

UniProt accession

Q9HBH9

MAP kinase-interacting serine/threonine-protein kinase 2

UniProt accession via ChEMBL component mapping As of 2026-09-14

www.uniprot.org

Disease evidence contract

Open Targets-ready proxy

ChEMBL drug mechanism + indication proxy

ChEMBL drug mechanism + indication proxy As of 2026-09-14

www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?

UniProt Target Context

UniProt accession via ChEMBL component mapping

Start here when your first question is whether MAP kinase-interacting serine/threonine-protein kinase 1/2 is the right protein anchor across sources, using UniProt Q9HBH9 as the stable mapping.

Jump to Protein Context

Need disease fit before discussing compounds?

Disease Relevance & Evidence Level

ChEMBL drug mechanism + indication proxy

Use this block first when you need to confirm why cancer is currently framed as clinical signal support. It currently carries 1 linked drug in the same disease frame.

Jump to Disease Context

Need a meeting-ready explanation of why this target matters?

Evidence Card

Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card

Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

Preferred Name	MAP kinase-interacting serine/threonine-protein kinase 1/2
Target Type	PROTEIN FAMILY
Organism	Homo sapiens
UniProt	Q9HBH9

ChEMBL ↗ UniProt ↗ NCBI Protein ↗

Next Actions

SearchRun a focused querySearch the database using this target name as the starting context. ApprovalsCheck approved moleculesSee which approved drugs connect back to this target and its surrounding signal space. FeedScan papers & updatesStay in the project thread while checking recent papers and platform updates.

UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein Label	MAP kinase-interacting serine/threonine-protein kinase 2
UniProt Accession	Q9HBH9
Component Type	Protein
Sequence Length	465 aa

MAP kinase-interacting serine/threonine-protein kinase 2

Source · UniProt accession via ChEMBL component mapping Freshness · Sep 14, 2026, 10:42 AM KST As of · Sep 14, 2026

UniProt Context ↗

Review Cue

How to read this target

Review this target as MAP kinase-interacting serine/threonine-protein kinase 1/2, mapped to UniProt Q9HBH9. ChEMBL maps the protein component as MAP kinase-interacting serine/threonine-protein kinase 2. Sequence length is 465 aa.

Mapped IDQ9HBH9

Review nameMAP kinase-interacting serine/threonine-protein kinase 1/2

OrganismHomo sapiens

Disease Relevance

Disease Relevance & Evidence Level

Open Targets-ready disease context using the current target-indication evidence contract.

Clinical signal Open Targets-ready proxy

MAP kinase-interacting serine/threonine-protein kinase 1/2 shows clinical signal disease relevance led by cancer. 5 more disease programs remain visible in the same review block.

Clinical signal Phase II

cancer